Balance Sheet
Cash Flow Statement
Asset Writedowns and ImpairmentCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in IntangiblesChange in InventoryChange in ReceivablesDeferred TaxesDepreciation & Amortization (CF)Depreciation and DepletionFree Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeOther Working Capital ChangesOther financing activitiesShare-based CompensationShares RepurchasedShort-Term Debt issuances
Daily Values
Growth Metrics
Income Statement
Others
Ratios

United Therapeutics (UTHR) Long-Term Debt Repayments (2016)

United Therapeutics (UTHR) has disclosed Long-Term Debt Repayments for 2 consecutive years, with $900000.0 as the latest value for Q3 2016.

  • Quarterly Long-Term Debt Repayments fell 67.86% to $900000.0 in Q3 2016 from the year-ago period, while the trailing twelve-month figure was $8.8 million through Dec 2016, down 93.39% year-over-year, with the annual reading at $8.8 million for FY2016, 93.39% down from the prior year.
  • Long-Term Debt Repayments hit $900000.0 in Q3 2016 for United Therapeutics, down from $7.8 million in the prior quarter.
  • In the past five years, Long-Term Debt Repayments ranged from a high of $90.3 million in Q2 2015 to a low of $100000.0 in Q1 2016.